New Model For Real World Evidence? Leqembi Registry Data Will Be Bolstered By Medicare Claims

Senior Centers for Medicare and Medicaid Services official Lee Fleisher described the game plan behind the CMS-facilitated patient registry for the new Alzheimer’s disease treatment, but former CMS official Sean Tunis is still concerned the approach won’t meet data expectations in the planned two-year window.

CMS is Using Its Coverage Clout and Medicare Claims To Generate Real World Evidence. • Source: Shutterstock

The Centers for Medicare and Medicaid Services will link Medicare claims data on Alzheimer's to supplement the data from its bare-bones registry on Eisai Co., Ltd. and Biogen, Inc.’s Leqembi, a new treatment for the disease.

CMS announced specifics on its patient registry after the US Food and Drug Administration’s traditional approval of Leqembi on 6...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet